TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 174 filers reported holding TRAVERE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.74 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,694 | -35.1% | 4,440 | +11.5% | 0.00% | -33.3% |
| Q2 2023 | $61,179 | -22.1% | 3,983 | +14.1% | 0.00% | -25.0% |
| Q1 2023 | $78,535 | -1.9% | 3,492 | -8.3% | 0.00% | 0.0% |
| Q4 2022 | $80,061 | -9.1% | 3,807 | +6.5% | 0.00% | 0.0% |
| Q3 2022 | $88,088 | -9.1% | 3,575 | -10.6% | 0.00% | 0.0% |
| Q2 2022 | $96,872 | -6.0% | 3,998 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $103,028 | -79.9% | 3,998 | -75.7% | 0.00% | -42.9% |
| Q4 2021 | $511,322 | +28.0% | 16,473 | 0.0% | 0.01% | +16.7% |
| Q3 2021 | $399,470 | +66.2% | 16,473 | 0.0% | 0.01% | +100.0% |
| Q2 2021 | $240,341 | -38.5% | 16,473 | +5.3% | 0.00% | -50.0% |
| Q1 2021 | $390,706 | – | 15,647 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |